Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Legislation In Brief

This article was originally published in The Gray Sheet

Executive Summary

Brachyatherapy coverage: Brachytherapy devices would be excluded from the hospital outpatient prospective payment system under bill introduced by Rep. Nathan Deal (R-Ga.) March 11. The bill calls for the number, isotope and radioactive intensity to be paid for separately, including separate groups for palladium-103 and iodine-125, by creating additional groups of outpatient services and classifying them apart from other services. Theragenics (Theraseed palladium-103 seed) and the Coalition for the Advancement of Brachytherapy have been rebuffed repeatedly by CMS in attempts to get the agency to pay for prostate brachytherapy seeds separately, most recently in the 2003 OPPS final rule (1"The Gray Sheet" Nov. 11, 2002, p. 26). HR 1182 was referred to the Energy & Commerce and Ways & Means Committees...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT018045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel